Vanda Pharmaceuticals Inc announced that a HETLIOZ patent, number 10,071,977 (‘977 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book.  The ‘977 patent was issued by the United States Patent and Trademark Office on September 11, 2018 and expires in February 2035.  Prior to this newly listed ‘977 patent, the HETLIOZ Orange Book listed patent with the latest expiry date was set to expire in May 2034.